Latest news with #Otezla
Yahoo
21-05-2025
- Business
- Yahoo
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
Amgen's AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader macroeconomic uncertainty. Stocks have been on a roller-coaster ride since President Trump unveiled sky-high tariffs in early April and China came up with retaliatory tariffs. Last week, China and the United States struck a deal that eased trade tensions and resulted in a stock market recovery. Though the massive tariffs imposed by the United States and retaliatory tariffs by China and some other countries are now on a pause, it is only a temporary suspension, and no one knows what will happen after the 90-day tariff suspension ends. The uncertainty around tariffs and trade production measures remains, which has muted economic growth. Although pharmaceuticals have been exempted from tariffs in the first round, they could be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.' Let's understand AMGN's strengths and weaknesses to better analyze how to play the stock in the uncertain macro environment. Amgen's revenues grew 9% year over year in the first quarter of 2025, driven by growing patient demand for its innovative medicines. Amgen is seeing declining revenues from oncology biosimilars and some legacy established products like Enbrel. Pricing headwinds and competitive pressure are hurting sales of many products. Sales of some key brands, like Otezla and Lumakras, have been lukewarm. However, revenues from key older medicines like Prolia, Repatha and Blincyto and new drugs like Tavneos and Tezspire are driving the top line. Rare disease drugs like Tepezza, Krystexxa and Uplizna, added from last year's acquisition of Horizon Therapeutics, are also boosting top-line growth. Amgen is also evaluating Kyprolis, Otezla, Nplate, Repatha, Lumakras, Tezspire, Uplizna and Blincyto for additional indications. Approval for the expanded use of these drugs can potentially drive further top-line growth. Uplizna was approved for IgG4-related disease in the United States in April 2025. Amgen's regulatory application for Uplizna in myasthenia gravis is under review in the United States, with an FDA decision expected on Dec. 14, 2025. Tezspire is under review in the United States for chronic rhinosinusitis with nasal polyps, with an FDA decision expected on Oct. 19, 2025. Amgen has invested several billion dollars in M&A deals over the last decade, which has bolstered its product portfolio and diversified its pipeline. Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and, possibly, less frequent dosing. This key feature differentiates it from Eli Lilly's LLY and Novo Nordisk's NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections. In clinical studies, it has shown predictable and sustained weight loss and a meaningful impact on cardiometabolic parameters. In March, Amgen initiated two phase III studies on MariTide in obesity as part of its comprehensive MARITIME phase III program. Separate phase III studies on MariTide in obesity, with or without type II diabetes, are currently enrolling patients. Additional MARITIME phase III studies on MariTide in specific obesity-related conditions are expected to be launched throughout 2025. Separate phase II studies on obesity and type II diabetes are also ongoing, with data readouts expected in the second half. An interesting BiTE drug, Imdelltra (tarlatamab), was approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024. Several phase III studies are currently ongoing on tarlatamab in earlier-line settings across extensive-stage and limited-stage SCLC. Imdelltra is believed to have blockbuster potential, as there are limited treatment options in late-line SCLC. Another important candidate, rocatinlimab, is being evaluated in phase III studies for atopic dermatitis and prurigo nodularis. Several data readouts are expected over the next six to 12 months, which could be important catalysts for the stock. Amgen has successfully launched some new biosimilar products this year, which generated impressive sales in the first quarter. In January, Amgen launched Wezlana, the first biosimilar version of J&J's JNJ blockbuster drug, Stelara. Wezlana generated sales of $150 million in the quarter. Wezlana was approved by the FDA in 2023 but was not launched until January 2025, as per a settlement with J&J. Amgen launched the first biosimilar version of Regeneron's Eylea, Pavblu, in the fourth quarter of 2024, which generated sales of $99 million in the first quarter of 2025. Another key biosimilar product, Bekemv, a biosimilar version of AstraZeneca's Soliris, was approved in the United States in May 2024 and was launched in the second quarter of 2025. In the first quarter of 2025, Amgen's biosimilar products generated impressive sales of $735 million, which rose 35% year over year. Amgen's new biosimilar launches will play a key role in mitigating the impact of Amgen's upcoming loss of exclusivity (LOE) over the next few years. Phase III studies are ongoing to evaluate biosimilar versions of Bristol-Myers' Opdivo (ABP 206), Merck's Keytruda (ABP 234) and Roche's Ocrevus (ABP 692). Patents for RANKL antibodies (including sequences) for Prolia and Xgeva expired in February 2025 in the United States and will expire in November 2025 in some European countries. Sales of these best-selling drugs are expected to erode significantly in 2025, mainly in the second half, due to patent erosion. Sales of Amgen's rare disease drugs, mainly Tepezza, have slowed down, which is a concern. The Medicare Part D redesign is expected to hurt sales of some of Amgen's drugs in future quarters. Enbrel and Otezla have been selected by the Centers for Medicare & Medicaid Services for Medicare Part D price setting beginning in 2026 and 2027, respectively. Pricing headwinds and competitive pressure are hurting sales of many products. Weakness in some key brands like Otezla and Lumakras creates potential revenue headwinds. Amgen's stock has risen 7.3% so far this year against a decrease of 3.1% for the industry. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below. Image Source: Zacks Investment Research From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 13.12 forward earnings, which is lower than 14.74 for the industry. The stock is also trading below its five-year mean of 13.80. Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $20.59 to $20.79 per share for 2025 over the past 30 days. For 2026, the consensus mark for earnings has risen from $21.19 to $21.23 per share over the same timeframe. Image Source: Zacks Investment Research After analyzing the factors discussed above, we believe the company is well placed to maintain long-term revenue growth, driven by continued strong volume growth of key drugs, Repatha, Evenity and Prolia and increasing contribution from new innovative medicines like Tezspire, Tavneos and Imdelltra. It is expected to see continued clinical success from its mid- to late-stage pipeline. Though the initial data from MariTide studies were below expectations, MariTide has the potential to be a game-changer for Amgen. Along with all these factors, Amgen's consistently rising estimates, reasonable valuation and decent stock price appreciation are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested for now. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Associated Press
14-04-2025
- Business
- Associated Press
Johnson & Johnson's Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson's recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According to the company's recent release, the once-daily oral therapy met all primary and secondary endpoints across both the FRONTIER 1 and FRONTIER 2 studies in moderate-to-severe plaque psoriasis, achieving 65% PASI 90 response and 74% IGA 0/1 at Week 24 with its higher dose regimen. These efficacy outcomes and a favorable safety profile suggest that icotrokinra may become the first oral IL-23 pathway inhibitor to reshape the current psoriasis treatment algorithm. Data from Spherix Global Insights' RealTime Dynamix™: Plaque Psoriasis (US) Q1 2025 report confirms heightened interest in icotrokinra among dermatologists (n=103), with many already envisioning its role as a first-line systemic treatment. While unaided awareness of the Phase 3 results was modest, prompted exposure to the data led to a significant uptick in prescriber enthusiasm. In fact, dermatologists rated icotrokinra as the top pipeline agent by a considerable margin, and they would like to see it approved, with interest and likelihood to prescribe scores surpassing all other late-stage psoriasis assets. Notably, over half of dermatologists reported that icotrokinra would be used as a first-line advanced systemic treatment. At the same time, most agree that its availability would expand the pool of psoriasis patients on advanced treatments—a strong indicator that icotrokinra may help bridge the gap between topical and biologic therapies. Importantly, a sizable portion of patients currently treated with oral small molecules (i.e., Otezla or Sotyktu) who are not considered well-managed may be switched to icotrokinra upon availability, underscoring its potential to disrupt the existing oral systemic market. Dermatologists cited its oral convenience, high response rates, and mechanistic familiarity with successful IL-23 biologics like Skyrizi and Tremfya as primary drivers of interest. Data from Spherix's Special Topix™: The Oral Opportunity in Plaque Psoriasis, 2024 study indicate that the availability of efficacious and safe oral agents is the top unmet need for treating psoriasis. Moreover, most dermatologists believe that oral treatment can be just as efficacious as injectable treatment. Despite the positive momentum, some prescribers remain cautiously optimistic, pointing to the need for real-world data and long-term safety monitoring before making widespread practice changes. However, with robust Phase 3 results and clear differentiation from existing oral therapies, icotrokinra is poised to be a game-changer in moderate-to-severe plaque psoriasis. As J&J advances icotrokinra toward regulatory submission, ongoing dermatologist perception tracking will be critical in determining its commercial potential and ultimate impact on the psoriasis landscape. Spherix continues to monitor the PsO market with these insights and more available via its quarterly RealTime Dynamix™ service, and will continuously evaluate the oral opportunities in psoriasis via the Special Topix™ service. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Andy Stankus, Dermatology Franchise Head Spherix Global Insights 4848794284 [email protected]
Yahoo
14-04-2025
- Business
- Yahoo
Johnson & Johnson's Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson's recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According to the company's recent release, the once-daily oral therapy met all primary and secondary endpoints across both the FRONTIER 1 and FRONTIER 2 studies in moderate-to-severe plaque psoriasis, achieving 65% PASI 90 response and 74% IGA 0/1 at Week 24 with its higher dose regimen. These efficacy outcomes and a favorable safety profile suggest that icotrokinra may become the first oral IL-23 pathway inhibitor to reshape the current psoriasis treatment algorithm. Data from Spherix Global Insights' RealTime Dynamix™: Plaque Psoriasis (US) Q1 2025 report confirms heightened interest in icotrokinra among dermatologists (n=103), with many already envisioning its role as a first-line systemic treatment. While unaided awareness of the Phase 3 results was modest, prompted exposure to the data led to a significant uptick in prescriber enthusiasm. In fact, dermatologists rated icotrokinra as the top pipeline agent by a considerable margin, and they would like to see it approved, with interest and likelihood to prescribe scores surpassing all other late-stage psoriasis assets. Notably, over half of dermatologists reported that icotrokinra would be used as a first-line advanced systemic treatment. At the same time, most agree that its availability would expand the pool of psoriasis patients on advanced treatments—a strong indicator that icotrokinra may help bridge the gap between topical and biologic therapies. Importantly, a sizable portion of patients currently treated with oral small molecules (i.e., Otezla or Sotyktu) who are not considered well-managed may be switched to icotrokinra upon availability, underscoring its potential to disrupt the existing oral systemic market. Dermatologists cited its oral convenience, high response rates, and mechanistic familiarity with successful IL-23 biologics like Skyrizi and Tremfya as primary drivers of interest. Data from Spherix's Special Topix™: The Oral Opportunity in Plaque Psoriasis, 2024 study indicate that the availability of efficacious and safe oral agents is the top unmet need for treating psoriasis. Moreover, most dermatologists believe that oral treatment can be just as efficacious as injectable treatment. Despite the positive momentum, some prescribers remain cautiously optimistic, pointing to the need for real-world data and long-term safety monitoring before making widespread practice changes. However, with robust Phase 3 results and clear differentiation from existing oral therapies, icotrokinra is poised to be a game-changer in moderate-to-severe plaque psoriasis. As J&J advances icotrokinra toward regulatory submission, ongoing dermatologist perception tracking will be critical in determining its commercial potential and ultimate impact on the psoriasis landscape. Spherix continues to monitor the PsO market with these insights and more available via its quarterly RealTime Dynamix™ service, and will continuously evaluate the oral opportunities in psoriasis via the Special Topix™ service. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Andy Stankus, Dermatology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
24-02-2025
- Business
- Yahoo
Global Skin Repair Market to Worth Over US$ 149.52 Billion by 2033
Driven by natural ingredient demand and infection prevention technologies, the skin repair sector faces challenges in product efficacy and consumer trust. Gender-neutral solutions emerge as a key trend. New Delhi, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The global skin repair market was valued at US$ 81.67 billion in 2024 and is expected to reach US$ 149.52 billion by 2033 at a CAGR of 6.95% during the forecast period 2025–2033. Advancements in skin repair drugs are creating a vibrant and promising market driven by robust clinical demand and evolving consumer preferences. In the United States, skin treatments are growing at an annual rate of 4.73% from 2025 to 2033, while prescription drug spending is expected to increase between 10.0% and 12.0% in 2024, with clinics and hospitals reporting an 11.0% uptick. Topical creams and ointments already capture 30% of the skin repair market, reflecting their widespread use. The diabetic foot ulcers segment is the fastest-growing application, and conditions such as acne—affecting 50 million Americans annually—and atopic dermatitis—which impacts nearly one in ten individuals—underscore the urgent need for effective therapies. Globally, dermatological products are set to grow at a CAGR of 11.5% from 2025 to 2030. Moreover, most consumers in the market are between 20 and 30 years old, with females showing a higher preference for these products. Rising demand is also noted for non-invasive treatments, natural and organic ingredients popular in North America, anti-aging solutions, and advanced wound care products, all of which are converging to drive innovation in skin repair drug development. Download Free Sample Pages @ In parallel, technological innovations and personalized care strategies are fueling growth in the skin repair market. Increasing adoption of artificial intelligence and telemedicine is driving demand for customized skincare, as social media and beauty influencers boost consumer awareness by 20–30%. Environmental challenges, including pollution and UV exposure, contribute to a 15–25% rise in demand for protective and reparative treatments. Recent drug approvals such as Rinvoq for psoriatic arthritis and Otezla for moderate to severe psoriasis underscore the shift toward innovative therapies. Advanced drug delivery systems—including nano, micro, and macro-scale technologies—have experienced a 30–40% increase in demand, offering efficient, targeted delivery of active compounds. Research in cell-based therapies and bioengineered skin grafts is growing by 20–25%, promising transformative approaches for complex skin injuries. The adoption of microneedle technology for transdermal delivery in psoriasis and atopic dermatitis is rising by 15–20%. These advancements harmonize traditional topical therapies with cutting-edge innovations, paving the way for a comprehensive patient-centric approach to skin repair. With continued progress and integration of technologies, the future of skin repair drugs appears promising, meeting consumer needs and overcoming challenges. Key Findings in Skin Repair Market Market Forecast (2033) US$ 149.52 billion CAGR 6.95% Largest Region (2024) North America (40%) By Product Type Cream & Ointments (30%) By Product Form Ointments (31%) By Application Diabetic Foot Ulcers (25%) By End Users Hospitals (55%) Top Drivers Infection prevention through advanced skin repair technologies Tissue regeneration advancements enhancing skin repair efficacy Increasing demand for natural and organic skin repair solutions Top Trends Rise of personalized skin repair treatments using AI and data analytics Growth in demand for eco-friendly and sustainable skin repair products Expansion of gender-neutral skin repair solutions catering to diverse demographics Top Challenges Managing adverse drug reactions and ensuring product safety Addressing environmental and lifestyle impacts on skin health Overcoming consumer skepticism towards new skin repair technologies Innovative Technological Advancements Driving the Global Skin Repair Market Forward In 2024, technological innovations continue to propel the skin repair market into a new era of efficiency and precision. Over 10,000 dermatology practices now rely on AI-powered diagnostic tools that process over 1 million images per day to aid in accurate skin condition analysis. These advanced tools have notably reduced diagnostic errors, achieving error rates that are substantially lower than traditional methods. The incredible performance of these AI systems has inspired the dermatology community to integrate them widely in clinical workflows, underscoring a movement toward more personalized and safe skin repair treatments. Such progress is a testament to the industry's commitment to leveraging technology for improved health outcomes. At the forefront of these developments, nanotechnology has begun to redefine product performance in the skincare sector. More than 500 innovative skincare products utilizing nanoparticles have been introduced, significantly enhancing the penetration of active ingredients. In parallel, over 1,000 customized skin repair formulations have been developed that cater specifically to individual genetic and microbiome profiles in the skin repair market; this personalized approach has produced measurable improvements in treating chronic skin conditions. Cutting-edge 3D bioprinting technology is now utilized by 50 leading research institutions to create artificial skin models, streamlining the testing and development of novel treatments. Each innovation, whether in AI diagnostics or nanotechnology-enabled formulations, not only reinforces the commitment to excellence but also firmly establishes the skin repair sector as a model of modern scientific integration and trust. Consumer Behavior Shifts: Embracing Advanced Skin Repair Solutions Proactively Today Consumer behavior in skin repair market marked by an informed shift towards advanced skin repair products, powered by digitally enabled education and widespread social media influence. In the United States alone, more than 75 million consumers now incorporate at least one innovative skin repair product into their daily regimen. Social media has played a pivotal role, with skincare influencers reaching over 500 million followers, thereby spreading knowledge and trust in cutting-edge products and practices. This growing digital dialogue empowers consumers to make well-informed decisions based on both clinical evidence and firsthand testimonials. Today's consumers are not only active but also educated stakeholders, ensuring that innovative products are used for both immediate improvement and long-term care. Educational outreach has become central to inspiring these shifts in the skin repair market. More than 20 million individuals have participated in online skincare education programs sponsored by reputable dermatology brands. This has led to a consumer base that is increasingly savvy—65% of users can now identify at least five active ingredients in their products. Meanwhile, a clear preference for natural and organic formulations is evident, with over 30 million consumers opting solely for certified products. Moreover, 40 million individuals now embrace skin repair as a key component of their holistic wellness routines. With such strong engagement, consumer trust aligns with scientific advancements and industry expertise, reinforcing the message that informed care is the cornerstone of modern dermatology. Sustainability and Ethics: New Pillars Transforming Skin Repair Product Authenticity Sustainability and ethical practices have rapidly become the new benchmarks for innovation in the skin repair market. Driven by a clear consumer mandate for responsible production, over 5,000 skincare brands have adopted fully sustainable packaging solutions, collectively eliminating more than 100,000 tons of plastic waste annually. Additionally, 70% of new product launches now feature at least 50% recycled materials in their packaging. This commitment to environmental responsibility is complemented by strong ethical sourcing practices; 3,000 brands are now certified cruelty-free while 2,500 adhere to fair trade standards. These initiatives ensure that consumers receive products that are both high-quality and ethically produced. Transparency in ingredient sourcing has been further enhanced through modern blockchain technology adopted by over 1,500 skincare brands. This technological shift provides consumers with verifiable insights into the supply chain and reinforces brand authenticity. The increased demand for vegan formulations is echoed by 10 million consumers who exclusively purchase vegan-certified skincare products. In production, water conservation remains a top priority in skin repair market, with firms implementing recycling systems that collectively save over 500 million liters of water each year. With the rollout of 200 new sustainable ingredients in 2024, the industry continues to innovate responsibly. These advancements are not only scientifically significant but also build trust and authority within a market where ethical practices and environmental stewardship are paramount. Regulatory Landscape Navigation: Compliance and Innovation in Skin Repair Market Trends Regulatory bodies across the globe are evolving standards to ensure skin repair market products are both safe and effective in today's dynamic landscape. In 2024, the FDA has mandated comprehensive safety assessments for over 1,000 widely used skincare ingredients. This initiative has given rise to 50 specialized testing facilities dedicated solely to evaluating product safety, thereby ensuring that every formulation adheres to stringent clinical criteria. The European Union has also expanded its list of restricted substances, adding 200 new compounds to existing guidelines—all aimed at protecting consumer health and reinforcing industry integrity. These developments are a clear demonstration of regulatory commitment to excellence, aimed at bolstering public trust. To stay compliant, over 80% of manufacturers now invest heavily in advanced quality control systems alongside blockchain-based traceability, which is being employed by 500 skincare brands. New guidelines regulating natural and organic claims now influence over 5,000 product formulations in the global skin repair market, ensuring consumers receive accurate information about ingredient origins. The rise of personalized skincare formulation has also been addressed through the creation of 20 new regulatory frameworks, specifically crafted to assess the safety of individualized products. Additionally, the implementation of eco-labeling standards has resulted in 3,000 products bearing clear environmental impact labels. Such rigorous oversight not only elevates product safety but also enhances consumer trust, a cornerstone in building long-term brand authority and aligning with global regulatory expectations. Modify this report as per your specific needs: Global Market Dynamics: Regional Skin Repair Trends Driving Consumer Engagement The demand for innovative skin repair market products is not uniform around the globe; rather, distinct regional trends highlight diverse consumer preferences and cultural influences. In Asia, traditional beauty ideals meld with technology, as evidenced by South Korea exporting over 5 billion units of skincare products annually. Meanwhile, Chinese consumers have embraced skin repair solutions enriched with traditional herbal ingredients, with 100 million individuals integrating Chinese medicine into their daily skincare routines. Europe continues to lead the clean beauty movement, where nearly every new product launch features natural and organic ingredients. Such trends highlight how age-old traditions and modern science converge to meet consumer needs. North America and Latin America are also setting trends in skin repair market. In North America, over 10 million consumers now rely on AI-powered skin analysis apps to personalize their skincare routines, demonstrating a clear demand for digital health solutions. Latin American consumers favor products that offer multifunctional benefits, with a large segment preferring formulations that provide at least three distinct skincare benefits. The Middle East is emerging as a luxury skincare hub, with high-end products experiencing robust annual growth. In Africa, local innovation is thriving; 500 new skin repair products featuring indigenous botanicals were launched in 2024, reflecting a deep respect for regional botanical traditions. These diverse global trends underline the importance of cultural relevance, technological integration, and regional authenticity—all of which contribute to an increasingly engaged and informed consumer base. Global Skin Repair Market Major Players: NeoAsia Lutronic Lynton Venus Concept Cynosure Sciton Strata Skin Sciences Syneron Candela Cutera Lumenis Solta Medical Other Prominent Players Key Segmentation: By Product Form Creams Ointments Gels Pads and Dressings Other Forms By Product Type Topical Creams and Ointments Moisturizers and Lotions Serums and Elixirs Wound Care Products Skin Repair Devices By Application Burns Diabetic Foot Ulcers Surgical Wounds Traumatic Wounds Pressure Sores Others By Distribution Channel Retail Pharmacies Online Retail Hospital Pharmacies Specialty Stores Others By End-user Hospitals and Clinics Home Care Settings Skincare and Aesthetic Centers Others By Region North America Europe Asia Pacific Middle East & Africa South America Have questions? Get expert guidance before purchasing: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio
